RecruitingNot ApplicableNCT07216976

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study


Sponsor

MedtronicNeuro

Enrollment

62 participants

Start Date

Nov 19, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the study is to evaluate the effectiveness of the Medtronic Adaptive DBS therapy (aDBS) for Parkinson's Disease in China with the Percept family of Implantable Neurostimulators (Percept PC and Percept RC).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a smarter, adaptive version of deep brain stimulation (DBS) for people with Parkinson's disease. Standard DBS delivers a constant electrical signal to the brain, but this study tests a system that automatically adjusts based on real-time brain signals, potentially providing better symptom control. **You may be eligible if...** - You have been diagnosed with Parkinson's disease - You already have a Medtronic Percept PC or Percept RC DBS device implanted (for at least 3 months) - Your DBS settings and medications have been stable for at least 4 weeks - Your doctor believes your DBS therapy is helping you - You are able to attend all study visits and complete required questionnaires **You may NOT be eligible if...** - You do not already have the compatible Medtronic DBS device - Your DBS or medications have been changed recently - You are pregnant or planning to become pregnant - You are unable to comply with study procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPercept™ PC and Percept RC with Adaptive DBS (aDBS™)

Subjects for whom meet the LFP screening criteria and can be acceptably configured on the "Best" aDBS mode (Dual or Single Threshold) will receive "Best" Mode aDBS treatment and enter the aDBS Evaluation Phase.


Locations(5)

Xuanwu Hospital

Beijing, Beijing Municipality, China

Sun Yat-sen Hospital

Guangzhou, Guangdong, China

Huashan Hospital

Shanghai, Shanghai Municipality, China

Ruijin Hospital

Shanghai, Shanghai Municipality, China

West China Hospital

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07216976


Related Trials